Cannabis Law Report

DECEMBER 14, 2019

Medical cannabis was legalized in Australia in 2016 when the Narcotic Drugs Act was amended, allowing cannabis to be grown for medical and scientific purposes. According to Australian marijuana research firm FreshLeaf Analytics, during Q3 of 2019, 76 new products were introduced in the market, up from 54 in Q1.

Pharmaceutical 98

Pharmaceutical Patients Clinical Trials Hemp 98

Healer

MARCH 26, 2021

In December, Sulak published results of his own 2016 study in which 85 percent of the 525 Integr8 Health patients surveyed reported a decrease or cessation in their opioid use when using medical cannabis. The researchers stressed the need for large, well-designed clinical trials. WHAT ABOUT CBD?

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

TheAnswerPage

JANUARY 11, 2022

Some patients put faith in anecdotal reports or the encouraging results of observational studies, but anecdotal reports and observational studies are not double blind randomized controlled clinical trials and do not prove that a treatment is or is not effective. Published 2019 May 6. Available at: [link] Accessed 05 Dec.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 21, 2021

All three industries are target markets from Dalrada’s original expansion plan that started in 2019. According to Fundera, these industries anticipate 115 – 121% job growth over ten years (2016-2026). billion in 2019 Q3. Yet, more than half of the people in the least developed countries lack access to electricity.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JANUARY 21, 2020

Below are the numbers of approvals for unapproved products during 2019 via Category B of the Special Access Scheme (SAS). A single patient may have had multiple approvals over the course of 2019. Issues including accessibility and cost are part of a wide-ranging Australian Senate inquiry into current patient access barriers.

Access 59

Access Patients Clinical Trials Medicine 59

The Cannigma

JANUARY 13, 2023

The authors noted that while “promising data are emerging on the possible role of ECS in migraine…proper placebo-controlled trials are needed to establish a therapeutic role for cannabinoids.” A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3% headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JUNE 11, 2019

June 6 2019. Despite the recent legalization of cannabis, a framework for access to cannabis for medical purposes still exists, but under new regulations passed under the authority of the Cannabis Act. White , 2016 BCSC 569. Kaur , 2016 BCSC 692. Ahn , 2016 BCSC 795, reversed on other grounds 2017 BCCA 221.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 3, 2019

The ACT Legislative Assembly voted to legalise the personal possession and cultivation of cannabis on 25 September 2019. Professor John McMillan AO’s review was conducted on the extensive amendments made to the ND Act in 2016, which established a regime for the cultivation, production and manufacture of medicinal cannabis in Australia.

Medicine 40

Medicine Research and Development Cultivation Supply Chain 40

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. In 2019, boxing legend, Mike Tyson, smoked a drug derived from toad venom (5-MeO-DMT). Zach’s been writing it since May of 2019.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51